A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy

Despite being a mainstay of clinical cancer treatment, chemotherapy is limited by its severe side effects and inherent or acquired drug resistance. Nanotechnology-based drug-delivery systems are widely expected to bring new hope for cancer therapy. These systems exploit the ability of nanomaterials...

Full description

Bibliographic Details
Main Authors: Dandan Zhu, Huanle Zhang, Yuanzheng Huang, Baoping Lian, Chi Ma, Lili Han, Yu Chen, Shengmei Wu, Ning Li, Wenjie Zhang, Xiaoxuan Liu
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/13/7/1092
id doaj-d27c1cb2261f4bc2a863e930d12f317a
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Dandan Zhu
Huanle Zhang
Yuanzheng Huang
Baoping Lian
Chi Ma
Lili Han
Yu Chen
Shengmei Wu
Ning Li
Wenjie Zhang
Xiaoxuan Liu
spellingShingle Dandan Zhu
Huanle Zhang
Yuanzheng Huang
Baoping Lian
Chi Ma
Lili Han
Yu Chen
Shengmei Wu
Ning Li
Wenjie Zhang
Xiaoxuan Liu
A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy
Pharmaceutics
amphiphilic peptide dendrimer
self-assembling
drug delivery
cancer therapy
author_facet Dandan Zhu
Huanle Zhang
Yuanzheng Huang
Baoping Lian
Chi Ma
Lili Han
Yu Chen
Shengmei Wu
Ning Li
Wenjie Zhang
Xiaoxuan Liu
author_sort Dandan Zhu
title A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy
title_short A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy
title_full A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy
title_fullStr A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy
title_full_unstemmed A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy
title_sort self-assembling amphiphilic peptide dendrimer-based drug delivery system for cancer therapy
publisher MDPI AG
series Pharmaceutics
issn 1999-4923
publishDate 2021-07-01
description Despite being a mainstay of clinical cancer treatment, chemotherapy is limited by its severe side effects and inherent or acquired drug resistance. Nanotechnology-based drug-delivery systems are widely expected to bring new hope for cancer therapy. These systems exploit the ability of nanomaterials to accumulate and deliver anticancer drugs at the tumor site via the enhanced permeability and retention effect. Here, we established a novel drug-delivery nanosystem based on amphiphilic peptide dendrimers (AmPDs) composed of a hydrophobic alkyl chain and a hydrophilic polylysine dendron with different generations (AmPD KK<sub>2</sub> and AmPD KK<sub>2</sub>K<sub>4</sub>). These AmPDs assembled into nanoassemblies for efficient encapsulation of the anti-cancer drug doxorubicin (DOX). The AmPDs/DOX nanoformulations improved the intracellular uptake and accumulation of DOX in drug-resistant breast cancer cells and increased permeation in 3D multicellular tumor spheroids in comparison with free DOX. Thus, they exerted effective anticancer activity while circumventing drug resistance in 2D and 3D breast cancer models. Interestingly, AmPD KK<sub>2</sub> bearing a smaller peptide dendron encapsulated DOX to form more stable nanoparticles than AmPD KK<sub>2</sub>K<sub>4</sub> bearing a larger peptide dendron, resulting in better cellular uptake, penetration, and anti-proliferative activity. This may be because AmPD KK<sub>2</sub> maintains a better balance between hydrophobicity and hydrophilicity to achieve optimal self-assembly, thereby facilitating more stable drug encapsulation and efficient drug release. Together, our study provides a promising perspective on the design of the safe and efficient cancer drug-delivery nanosystems based on the self-assembling amphiphilic peptide dendrimer.
topic amphiphilic peptide dendrimer
self-assembling
drug delivery
cancer therapy
url https://www.mdpi.com/1999-4923/13/7/1092
work_keys_str_mv AT dandanzhu aselfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT huanlezhang aselfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT yuanzhenghuang aselfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT baopinglian aselfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT chima aselfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT lilihan aselfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT yuchen aselfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT shengmeiwu aselfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT ningli aselfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT wenjiezhang aselfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT xiaoxuanliu aselfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT dandanzhu selfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT huanlezhang selfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT yuanzhenghuang selfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT baopinglian selfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT chima selfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT lilihan selfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT yuchen selfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT shengmeiwu selfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT ningli selfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT wenjiezhang selfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
AT xiaoxuanliu selfassemblingamphiphilicpeptidedendrimerbaseddrugdeliverysystemforcancertherapy
_version_ 1721286492043608064
spelling doaj-d27c1cb2261f4bc2a863e930d12f317a2021-07-23T14:00:53ZengMDPI AGPharmaceutics1999-49232021-07-01131092109210.3390/pharmaceutics13071092A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer TherapyDandan Zhu0Huanle Zhang1Yuanzheng Huang2Baoping Lian3Chi Ma4Lili Han5Yu Chen6Shengmei Wu7Ning Li8Wenjie Zhang9Xiaoxuan Liu10State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, ChinaDepartment of Analytical Chemistry, College of Science, China Pharmaceutical University, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, ChinaState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 210009, ChinaDespite being a mainstay of clinical cancer treatment, chemotherapy is limited by its severe side effects and inherent or acquired drug resistance. Nanotechnology-based drug-delivery systems are widely expected to bring new hope for cancer therapy. These systems exploit the ability of nanomaterials to accumulate and deliver anticancer drugs at the tumor site via the enhanced permeability and retention effect. Here, we established a novel drug-delivery nanosystem based on amphiphilic peptide dendrimers (AmPDs) composed of a hydrophobic alkyl chain and a hydrophilic polylysine dendron with different generations (AmPD KK<sub>2</sub> and AmPD KK<sub>2</sub>K<sub>4</sub>). These AmPDs assembled into nanoassemblies for efficient encapsulation of the anti-cancer drug doxorubicin (DOX). The AmPDs/DOX nanoformulations improved the intracellular uptake and accumulation of DOX in drug-resistant breast cancer cells and increased permeation in 3D multicellular tumor spheroids in comparison with free DOX. Thus, they exerted effective anticancer activity while circumventing drug resistance in 2D and 3D breast cancer models. Interestingly, AmPD KK<sub>2</sub> bearing a smaller peptide dendron encapsulated DOX to form more stable nanoparticles than AmPD KK<sub>2</sub>K<sub>4</sub> bearing a larger peptide dendron, resulting in better cellular uptake, penetration, and anti-proliferative activity. This may be because AmPD KK<sub>2</sub> maintains a better balance between hydrophobicity and hydrophilicity to achieve optimal self-assembly, thereby facilitating more stable drug encapsulation and efficient drug release. Together, our study provides a promising perspective on the design of the safe and efficient cancer drug-delivery nanosystems based on the self-assembling amphiphilic peptide dendrimer.https://www.mdpi.com/1999-4923/13/7/1092amphiphilic peptide dendrimerself-assemblingdrug deliverycancer therapy